DSIP Sleep Peptide: 2026 Dosing & Cat 1 Status

On July 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 6-7 to NOT recommend adding DSIP (Emideltide) to the §503A compounding bulk drug substances list. It was the only substance of the seven considered that the committee declined to advance. Compounded DSIP (Emideltide) therefore has no forward regulatory path in the United States at this time, and it remains a research-only substance. See our PCAC vote explainer for the full context.
DSIP (Delta Sleep-Inducing Peptide) is arguably the most pharmacologically interesting compound in the sleep peptide category, and also the most misunderstood. First isolated in 1977 by Monnier and Schoenenberger from the cerebral venous blood of rabbits induced into electrical sleep, this 9-amino-acid neuropeptide has accumulated almost five decades of research, the majority of it conducted in Switzerland, Russia, and former Soviet states. Despite that long history, DSIP has never been the subject of a large Western randomized controlled trial, which means it occupies an unusual position: a peptide with substantial mechanistic and clinical evidence from non-Western literature, but limited regulatory traction in the United States until very recently.
That changed in February 2026, when the FDA reclassified DSIP under the compounding name Emideltide and placed it on the Category 1 list. For people working with compounding pharmacies, this is one of the more notable wins of the recent reclassification cycle. This guide covers the science, the 2026 regulatory landscape, dosing math, stacking logic, and the practical questions users tend to ask after their first vial arrives.
Table of Contents
- What Is DSIP?
- How It Works
- DSIP vs Melatonin vs Other Sleep Aids
- Dosing Protocol
- Reconstitution Math
- Why the Short Half-Life But Long Effect?
- Stacking
- Side Effects
- Drug interactions
- Cycle Lengths
- Lab Monitoring
- Storage & Travel
- Beyond Sleep: Other DSIP Uses
- 2026 Regulatory Status
- Cost Considerations
- FAQ
- References
What Is DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was identified by Marcel Monnier and Guido Schoenenberger at the University of Basel, who perfused rabbits with electrical stimulation of the thalamus to induce sleep, then isolated the dialysate fraction responsible for transferring sleep activity to recipient animals. The 1977 publication by Schoenenberger and colleagues established the amino acid sequence and proposed DSIP as an endogenous sleep-promoting factor.
The naming situation in 2026 deserves a quick clarification. The research literature uniformly uses the name DSIP. The FDA, however, lists the compounding-grade form under the international nonproprietary name Emideltide. Both names refer to the same molecule. Compounding pharmacies operating under the post-February 2026 framework will typically label vials as Emideltide, sometimes with DSIP in parentheses. If you order from a Cat 1 compliant pharmacy and receive a vial labelled Emideltide, that is the correct product.
DSIP is unusual among sleep aids because it is not a sedative in the conventional pharmacological sense. It does not bind GABA receptors directly, it does not bind melatonin receptors, and it does not produce the next-day grogginess associated with hypnotics. Russian sleep researchers, most notably the group led by V.M. Kovalzon, have characterized DSIP as a modulator of slow-wave sleep architecture rather than a sleep initiator.
How It Works
The honest answer is that the mechanism of DSIP remains incompletely understood almost fifty years after its discovery. The literature has converged on several plausible and possibly overlapping pathways, none of which has been definitively established as primary.
- GABA-ergic facilitation. Several studies suggest DSIP indirectly potentiates GABAergic tone in thalamocortical circuits, although it does not bind GABA-A receptors directly.
- Opioidergic modulation. DSIP appears to interact with the endogenous opioid system, which may explain its reported utility in opioid and alcohol withdrawal syndromes documented in Russian clinical literature.
- ACTH and cortisol regulation. DSIP has been shown to attenuate ACTH release and lower stress-induced cortisol elevations, particularly in chronic stress paradigms.
- Slow-wave sleep architecture. The most consistent EEG finding across studies is increased delta-band power and improved continuity of stage 3 and 4 sleep, which is the original phenomenon Monnier and Schoenenberger were chasing.
The Kovalzon 2014 review summarizes the field bluntly: DSIP is best understood as a neuromodulator with broad homeostatic effects rather than a single-target ligand. This is part of why it has resisted the classical pharmacology playbook of receptor identification and selective agonist development.
DSIP vs Melatonin vs Other Sleep Aids
Sleep aids work on different layers of the sleep system, and lumping them together obscures what each one is actually good for. The table below frames where DSIP fits.
| Compound | Primary Action | Best For | Next-Day Grogginess |
|---|---|---|---|
| Melatonin | Circadian phase signal | Jet lag, delayed sleep phase | Low |
| GABAergics (Z-drugs, benzos) | Direct sedation | Sleep-onset insomnia | Moderate to high |
| Magnesium glycinate | Mild GABAergic, muscle relaxation | General sleep support | None |
| DSIP / Emideltide | Slow-wave sleep architecture | Fragmented sleep, low SWS, chronic stress | None reported |
The practical distinction is that melatonin tells your brain when to sleep, GABAergics force your brain to sleep, and DSIP appears to improve the quality of the sleep your brain is already trying to produce. People who fall asleep fine but wake up unrefreshed are the most consistent responders in user reports.
Dosing Protocol
Standard DSIP dosing in clinical and biohacking protocols falls in the 100 to 500 microgram range, administered subcutaneously 30 to 60 minutes before bed. Most users start at 100 mcg and titrate upward only if no effect is observed after seven to ten nights.
- Starting dose: 100 mcg subcutaneous, 30 to 60 minutes pre-bed.
- Standard range: 100 to 300 mcg for general sleep architecture support.
- Higher range: 300 to 500 mcg in chronic-pain or chronic-stress protocols, often paired with a longer cycle.
- Frequency: Pre-bed, nightly, with cycles typically running four to eight weeks.
Subcutaneous administration into the abdominal fat pad is the default route. Some Russian protocols use intranasal delivery, but injectable is the form supplied by US compounding pharmacies under the Emideltide listing.
Reconstitution Math
DSIP typically ships as a 5 mg lyophilized vial. Reconstitution with 2 ml of bacteriostatic water gives a working concentration of 2.5 mg per ml, or 2500 mcg per ml.
- 100 mcg dose = 0.04 ml = 4 units on a U-100 insulin syringe
- 200 mcg dose = 0.08 ml = 8 units
- 300 mcg dose = 0.12 ml = 12 units
- 500 mcg dose = 0.20 ml = 20 units
If you prefer to verify your math against your own vial size and BAC volume, the peptide reconstitution calculator handles arbitrary inputs and outputs insulin-syringe units directly.
Why the Short Half-Life But Long Effect?
One of the recurring puzzles in DSIP pharmacology is the disconnect between plasma kinetics and observed biological effects. The plasma half-life of DSIP is approximately seven minutes, which is short even by peptide standards. Yet EEG and behavioral effects have been reported the following day, and some Russian protocols describe carryover effects extending across multiple sleep cycles after a single dose.
The most parsimonious explanation, supported by Kovalzon and others, is that DSIP acts as a signaling trigger rather than a continuously occupying ligand. The peptide initiates a downstream cascade involving slow-wave-promoting circuits, and the cascade itself is what persists. This is similar in principle to how a hormone like growth hormone releasing hormone produces effects long outlasting its own clearance.
Practically, this means you should not interpret the seven-minute half-life as evidence the peptide stops working seven minutes after injection. The injection is a trigger event, not a sustained occupancy event.
Stacking
DSIP fits naturally into a broader sleep and stress optimization stack, and there are a few combinations worth knowing about.
- DSIP plus Selank. The cleanest pairing for circadian stress modulation. Selank covers daytime anxiolytic and cognitive support, DSIP covers nighttime sleep architecture. See the Selank guide for daytime dosing logic.
- DSIP plus Semax. Useful when daytime cognitive demand is high and sleep quality has been suffering. The Semax guide covers the morning-dose protocol.
- DSIP plus Ipamorelin. Ipamorelin is a clean GHRP without significant cortisol or prolactin effects, and pre-bed Ipamorelin pairs well with pre-bed DSIP. The Ipamorelin guide details the timing.
- Avoid: Older GHRPs such as GHRP-2 and GHRP-6 can produce cortisol spikes and disrupt sleep architecture, which works against what DSIP is doing. If you are using a GHRP, use Ipamorelin or stagger the older GHRP to the morning.
Side Effects
DSIP has one of the cleaner side effect profiles in the sleep peptide category, with most users reporting nothing notable across a full cycle. The effects that do come up are generally mild.
- Vivid dreams. The most commonly reported effect, consistent with deeper SWS and possibly increased REM rebound.
- Mild headache. Occasionally reported in the first few nights, usually resolving after the first week.
- Paradoxical insomnia. Rare but documented. A small subset of users report difficulty falling asleep on DSIP, which may reflect individual variation in opioidergic or HPA-axis response.
- Injection site reactions. Mild redness or tenderness, typical of any subcutaneous peptide.
No tolerance development or rebound insomnia on cessation has been documented in the published literature, although controlled long-term human data remains sparse.
Drug interactions
Drug interactions to know
Educational summary only, not medical advice. Consult your prescriber. See full interactions lookup.
Cycle Lengths
Cycling summary: Not typically cycled; used pre-bed as needed.
Chronic-use peptides like DSIP are typically continued as long as the treatment goal is active. Intentional pauses may be indicated for pregnancy planning, scheduled surgery, or transition to maintenance dosing (peptide-specific). See the peptide’s FDA prescribing information or your prescribing clinician for personalized guidance.
Lab Monitoring
DSIP is a cognitive/nootropic peptide. Lab monitoring covers both general health and any class-specific concerns (mood, sleep, hormonal axes when relevant).
Baseline (before starting): comprehensive metabolic panel (CMP) with LFTs and renal function, CBC, TSH, morning cortisol, vitamin D, B12, and lipid panel. Optional: a validated cognitive baseline (Cambridge Brain Sciences, Cogstate) and sleep tracking baseline via wearable if using DSIP for sleep-related outcomes.
During use: repeat CMP + CBC every 8-12 weeks. Track cognitive metrics and sleep quality on the same cadence as lab work. Watch mood shifts and log them.
What to flag to a physician: significant mood changes or emotional lability, sleep architecture disruption not present at baseline, persistent headache, cognitive changes that feel out of character, any lab shift outside reference range across two draws.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Freezer -20°C (-4°F) long-term; protect from light.
Reconstituted: Refrigerate 2-8°C (36-46°F); use within 21-28 days in BAC water; do not freeze. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.
International travel: DSIP is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.
Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.
Emergency out-of-fridge: reconstituted DSIP at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.
Beyond Sleep: Other DSIP Uses
The Russian clinical literature has explored DSIP well beyond its original indication. The Khvatova 1995 work and subsequent Russian publications describe applications including:
- Opioid withdrawal syndromes, where DSIP appears to attenuate craving and autonomic withdrawal symptoms.
- Alcohol withdrawal, with similar autonomic stabilization effects reported.
- Chronic pain, particularly in patients with comorbid sleep disruption, where the analgesic effect may be partly mediated through sleep restoration.
- Stress-related disorders, based on the ACTH-modulating actions described above.
It is worth being honest about the evidence base here. The Russian literature is real, peer-reviewed, and methodologically serious in places, but it does not substitute for Western Phase 3 data. Treat the non-sleep applications as plausible signals supported by clinical observation rather than as established indications.
2026 Regulatory Status
DSIP was placed on the FDA’s Category 1 reclassification list in February 2026 under the international nonproprietary name Emideltide. This means it is currently legal for compounding pharmacies operating under the 503A and 503B frameworks to compound and dispense the peptide for patients with a valid prescription. A scheduled regulatory review is on the calendar for July 2026, which could affirm or modify the current status, but as of late April 2026 the Cat 1 designation remains in effect.
For users, the practical implications are straightforward. A prescription is required. Your prescription should be issued by a licensed clinician and filled by a compounding pharmacy that lists Emideltide on its current formulary. Reputable pharmacies will provide a certificate of analysis on request.
Cost Considerations
Pricing for compounded Emideltide in the post-February 2026 environment has stabilized in a relatively narrow range. A 5 mg vial typically runs between 50 and 100 dollars from a US compounding pharmacy, with the exact price depending on pharmacy markup, shipping logistics, and whether you bundle with other peptides. At a 100 mcg nightly dose, a 5 mg vial provides 50 doses, which works out to roughly 1 to 2 dollars per night.
That is significantly more expensive than melatonin or magnesium, but cheaper per night than most prescription hypnotics, and the side-effect math is generally favorable.
FAQ
Is DSIP the same as melatonin?
No. Melatonin is a circadian signaling hormone that tells your brain when to initiate sleep. DSIP is a neuropeptide that appears to modulate the architecture of slow-wave sleep once you are asleep. They work on different layers of the sleep system and can be used together.
Will I feel groggy in the morning?
Next-day grogginess is not a typical DSIP effect. The seven-minute plasma half-life means the peptide itself is long gone by morning, and the downstream effects on sleep architecture tend to leave users feeling more rested rather than sedated.
Can I drive after taking it?
DSIP is taken pre-bed, so daytime driving is not the relevant question. If you are asking whether you can drive the morning after a dose, no impairment has been documented in the literature. That said, observe your own response for the first week before assuming this applies to you.
Is the Russian research reliable?
The Russian literature on DSIP is methodologically uneven, like most clinical literatures, but the core findings have been replicated across multiple groups over multiple decades, and the Kovalzon review provides a reasonable synthesis. The main caveat is that the Russian work generally lacks the sample sizes and pre-registration discipline of modern Western RCTs, so individual studies should be read as supporting evidence rather than as definitive.
How does it compare to magnesium glycinate?
Magnesium glycinate is a mild, broadly useful, low-cost sleep support that works through GABAergic and muscle-relaxation pathways. DSIP is more targeted at sleep architecture and is appropriate when basics like magnesium, sleep hygiene, and circadian alignment have been addressed and sleep quality is still poor. They are not substitutes for each other.
Can I cycle off without rebound insomnia?
Rebound insomnia on DSIP cessation has not been documented in the published literature. Anecdotal reports from long-cycle users generally describe a return to baseline sleep over several nights without overshoot. This contrasts favorably with GABAergic hypnotics, which are well known for rebound effects.
- Demand a current third-party Certificate of Analysis (CoA) listing peptide identity (mass spec), purity ≥98%, and endotoxin testing.
- Verify the lyophilized vial weight matches what is printed – under-filled vials are the most common form of dose-cheating in this market.
- Storage: Reconstituted DSIP stable 14 days refrigerated.
- Typical research route: subcutaneous (often pre-bed).
- Delta sleep-inducing peptide. Original 1970s rabbit research has not been robustly replicated in humans.
- “Research-use-only” labeling has legal weight – self-administration may violate state and federal law in your jurisdiction.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286. PubMed.
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-309. PubMed.
- Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. PubMed.
- Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-385. PubMed.
- Mendelson WB, Gillin JC, Dawson SD, Lewy A, Wyatt RJ. Effects of melatonin and propranolol on sleep of the rat. Brain Res. 1980;201(1):240-244. PubMed.
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. FDA.
- National Library of Medicine. PubMed search: DSIP delta sleep inducing peptide. PubMed.
- Schoenenberger GA, Maier PF, Tobler HJ, Monnier M. A naturally occurring delta-EEG-enhancing nonapeptide in rabbits. Pflugers Archiv. 1977;369(2):99-109.
- Khvatova EM, Rubanova NA, Prokhorova MV. Effect of DSIP on the activity of LDH and its isoenzymes in some structures of the rat brain. Voprosy Meditsinskoi Khimii. 1995;41(5):20-23.
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309.
- Kovalzon VM. The neurochemistry of the sleep-wakefulness cycle and the action of DSIP: a review of current data. In: Mechanisms of Sleep and Wakefulness. 2014.






